Center for Pharmacogenomic Studies

https://youtu.be/fd9kKkmV6nU

Frontiers in Addiction: Dr. Kevin McCauley November 21, 2017Frontiers in Addiction: Dr. Kevin McCauley

Clues Your Teen May Be Facing a Mental Health Challenge Signs your teen may be facing a mental health challenge.

We are committed to continuous innovation and enhancing the therapeutic relationship between healthcare provider and patient.

That’s why we are bringing you a new version of the GeneSight test, available today. We’ve added three medications – suvorexant (Belsomra®), lemborexant (Dayvigo®) and viloxazine (Qelbree®). Other refinements include revised categorization rules for amitriptyline, removal of clinical consideration 4 from paroxetine when variation is present in HTR2A, and updated phenotype language for the HLA genes. These enhancements to the GeneSight test are based on a comprehensive analysis of peer-reviewed literature.

The updated test is available for prescribing clinicians on starting today. If clinicians have previously ordered the test for patients, they may upgrade their report at no cost to the clinician or the patient though their myGeneSight.com portal.

Watch a video about the upgrade here: https://genesight.com/for-clinicians/